---
title: "Lyme disease incidence in England 2013–2024: updated multiplication factor and case trends"
id: "medrxiv-13-trends-in-lyme-disease-incidence-in-england-2013-to-2024"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-13-trends-in-lyme-disease-incidence-in-england-2013-to-2024"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.11.26362844v1?rss=1"
published_at: "2026-09-13T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Lyme disease incidence in England 2013–2024: updated multiplication factor and case trends
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-13-trends-in-lyme-disease-incidence-in-england-2013-to-2024
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.11.26362844v1?rss=1)
- **Published At:** 2026-09-13T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study analysed laboratory and primary care data from England covering 2013–2024 to reassess trends in symptomatic **Lyme disease** and update the factor used to estimate total cases from laboratory-confirmed counts. - Official incidence in England is based on **laboratory-confirmed** cases reported by the national reference laboratory, which underestimates total symptomatic cases because many diagnoses are made clinically without lab testing. - Authors used seasonal time series models on two data sources: national reference laboratory data and a primary care dataset (CPRD). Structural breaks were assessed using PELT and BinSeg methods and annual multiplication factors estimated with a Poisson regression model. - Results showed no substantial change in the number of laboratory-confirmed Lyme cases from 2013 to 2024 in England. - In contrast, cases diagnosed in **primary care** increased significantly over the same period, with an average rise of 498 additional primary care diagnoses per year. - The derived best estimate of the **multiplication factor** (to convert laboratory-confirmed cases to estimated total symptomatic cases) rose from 2.35 (95% CI 1.81–2.88) based on earlier data to 6.20 (95% CI 6.17–6.24), the average for 2020–2024. - The authors attribute part of the change to more recent clinical practice and guidance, noting the earlier multiplier was based on data from 1998–2016 and may be outdated after the 2018 national Lyme disease management guidance. - Use of the updated multiplication factor should improve the accuracy of annual symptomatic Lyme disease case estimates for England. - Data access and ethical notes: primary care data were extracted from the Clinical Practice Research Datalink (CPRD) and cannot be shared due to licensing restrictions. CPRD gave ethical approval (protocol 24_004190). Laboratory-confirmed data access requests should go to the UKHSA Office for Data Release. - The authors declared no competing interests and state that all relevant ethical guidelines were followed.
## Clinical Analysis & Structured Key Points
Trends in Lyme disease incidence in England, 2013 to 2024 | medRxiv Skip to main content Trends in Lyme disease incidence in England, 2013 to 2024 View ORCID Profile Janie C Olver , View ORCID Profile Mark Gideon Burdon , Eva Emanuel , Ali Datoo , Verena FermorDunman , Miranda Ferguson , Jessica I'Anson , Roberto Vivancos , Christina Petridou , Amanda Semper doi: https://doi.org/10.64898/2026.09.11.26362844 Janie C Olver 1 Rare and Imported Pathogens Laboratory, Emerging and Epidemic Infections Directorate, UK Health Security Agency, UK; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Janie C Olver For correspondence: janie.olver{at}ukhsa.gov.uk Mark Gideon Burdon 2 Infectious Disease Modelling Team, Analysis and Intelligence Assessment Directorate, UK Health Security Agency, UK; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Mark Gideon Burdon Eva Emanuel 3 Emerging Infections and Zoonoses, Emerging and Epidemic Infections Directorate, UK Health Security Agency, UK; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ali Datoo 3 Emerging Infections and Zoonoses, Emerging and Epidemic Infections Directorate, UK Health Security Agency, UK; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Verena FermorDunman 4 Data Innovation and Acquisition, Digital and Data Directorate, UK Health Security Agency, UK; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Miranda Ferguson 5 Blood Safety, Hepatitis, STIs and HIV, Public Health Infection Programmes Directorate, UK Health Security Agency, UK; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jessica I'Anson 6 National Field Services, Health Protection in Regions, UK Health Security Agency, UK Find this author on Google Scholar Find this author on PubMed Search for this author on this site Roberto Vivancos 6 National Field Services, Health Protection in Regions, UK Health Security Agency, UK Find this author on Google Scholar Find this author on PubMed Search for this author on this site Christina Petridou 1 Rare and Imported Pathogens Laboratory, Emerging and Epidemic Infections Directorate, UK Health Security Agency, UK; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Amanda Semper 1 Rare and Imported Pathogens Laboratory, Emerging and Epidemic Infections Directorate, UK Health Security Agency, UK; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Data/Code Preview PDF Abstract Official Lyme disease incidence figures for England are based on the number of cases with a laboratory-confirmed diagnosis from the national reference laboratory. However, these figures underestimate the true incidence of acute cases since patients can also be diagnosed clinically without the need for laboratory testing. The use of a multiplication factor has been proposed to estimate total Lyme disease incidence from the number of laboratory-confirmed cases. The current multiplication factor is derived from data spanning 1998 to 2016 and is thought to be outdated, in part due to the introduction of new national Lyme disease management guidance in 2018. The aim of this study was to analyse more recent laboratory and primary care data to identify trends in case numbers and to derive updated estimates of the total annual number of acute Lyme disease cases in England. Data spanning 2013 to 2024 from the national reference laboratory and a primary care data source were analysed using seasonal time series models. The presence of structural breaks was investigated using the PELT or BinSeg methods, and annual multiplication factors were estimated using a Poisson regression model. No substantial change was found in the number of laboratory-confirmed Lyme cases from 2013 to 2024 in England, whereas the number of cases diagnosed in primary care increased significantly over the same period, with an average of an additional 498 cases per year. This has increased our best estimate of the multiplication factor from 2.35 (95% confidence interval, 1.81 - 2.88) to 6.20 (6.17 - 6.24), which is the average for the years 2020 - 2024. Use of this updated multiplication factor should improve the accuracy of annual symptomatic Lyme disease case estimates for England. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Clinical Practice Research Datalink (CPRD) gave ethical approval for this work. The approved study protocol number is 24_004190. No further ethical approval was required. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability the primary care data were extracted from the Clinical Research Database Link (CPRD) and cannot be shared due to licensing restrictions. Applications for relevant anonymised laboratory-confirmed and referrals data should be submitted to the UKHSA Office for Data Release: https://www.gov.uk/government/publications/accessing-ukhsa-protected-data Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted September 13, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Trends in Lyme disease incidence in England, 2013 to 2024 Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Trends in Lyme disease incidence in England, 2013 to 2024 Janie C Olver , Mark Gideon Burdon , Eva Emanuel , Ali Datoo , Verena FermorDunman , Miranda Ferguson , Jessica I'Anson , Roberto Vivancos , Christina Petridou , Amanda Semper medRxiv 2026.09.11.26362844; doi: https://doi.org/10.64898/2026.09.11.26362844 Share This Article: Copy Citation Tools Trends in Lyme disease incidence in England, 2013 to 2024 Janie C Olver , Mark Gideon Burdon , Eva Emanuel , Ali Datoo , Verena FermorDunman , Miranda Ferguson , Jessica I'Anson , Roberto Vivancos , Christina Petridou , Amanda Semper medRxiv 2026.09.11.26362844; doi: https://doi.org/10.64898/2026.09.11.26362844 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Epidemiology Subject Areas All Articles Addiction Medicine (617) Allergy and Immunology (900) Anesthesia (330) Cardiovascular Medicine (4806) Dentistry and Oral Medicine (478) Dermatology (414) Emergency Medicine (648) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1626) Epidemiology (15929) Forensic Medicine (32) Gastroenterology (1202) Genetic and Genomic Medicine (7038) Geriatric Medicine (733) Health Economics (1064) Health Informatics (5035) Health Policy (1433) Health Systems and Quality Improvement (1760) Hematology (584) HIV/AIDS (1344) Infectious Diseases (except HIV/AIDS) (16285) Intensive Care and Critical Care Medicine (1171) Medical Education (667) Medical Ethics (153) Nephrology (722) Neurology (7262) Nursing (366) Nutrition (1080) Obstetrics and Gynecology (1240) Occupational and Environmental Health (1004) Oncology (3603) Ophthalmology (1049) Orthopedics (397) Otolaryngology (453) Pain Medicine (470) Palliative Medicine (139) Pathology (706) Pediatrics (1797) Pharmacology and Therapeutics (737) Primary Care Research (765) Psychiatry and Clinical Psychology (5887) Public and Global Health (9744) Radiology and Imaging (2415) Rehabilitation Medicine and Physical Therapy (1449) Respiratory Medicine (1247) Rheumatology (640) Sexual and Reproductive Health (771) Sports Medicine (578) Surgery (776) Toxicology (107) Transplantation (305) Urology (291)
## Related Clinical Research

- [IeDEA 2026 Site Assessment: Protocol for a Cross-Sectional Survey of HIV Clinics and Service Deliv](https://medichelpline.com/clinical-feed/medrxiv-12-documenting-hiv-service-delivery-and-adoption-of-evidence-based-practices-in.md)
- [Congenital syphilis risk similar for 6–8 vs 9‑day benzathine penicillin G dosing intervals in preg](https://medichelpline.com/clinical-feed/medrxiv-11-congenital-syphilis-outcomes-by-penicillin-dosing-intervals-among-women-with.md)
- [Case report: ADMIO type 1 linked to de novo STAT3 gain-of-function mutation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-case-report-of-admio-type-1-caused-by-a-de-novo-stat3-gain-of-function.md)
- [MMR vaccines: separating measles, mumps, rubella shots — myths and facts](https://medichelpline.com/clinical-feed/medical-news-today-0-should-the-measles-mumps-rubella-vaccines-be-separate-myths-vs-facts.md)
- [Kennedy renews attacks on vaccines at Children’s Health Defense conference](https://medichelpline.com/clinical-feed/stat-news-1-kennedy-renews-attacks-on-vaccines-at-children-s-health-defense-conference.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.